Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Botulinum toxin A for peripheral circulatory disorder in systemic sclerosis
jRCTs031260349Recruiting
- Start
- Jul 2026
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Open-label, single-arm trial of botulinum toxin type A in peripheral artery occlusion (PAD) and Raynaud disease. Primary endpoint: Primary responder rate for Raynaud's improvement at 4 weeks. Started Jul 2026; status: recruiting.
02
Drugs
botulinum toxin type A
03
Conditions
peripheral artery occlusion (PAD)Raynaud disease
Beyond the preview
Go deeper on jRCTs031260349.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031260349.